ACLX
Arcellx, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Arcellx (ACLX) Stock: Buy, Sell, or Hold?
$115.07
+0.04 (+0.03%)
â˛
5d:
+0.06%
30d:
+0.39%
90d:
+67.86%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: May 14, 2026
0d
Protect ACLX Gains
Updated Apr 27, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (64%)
Quality Score
50/100
Position
FAIR
Forward P/E & Valuation
-66.4x
Next 12M consensus est.
Wall Street Target
$112.85
-1.9% vs target
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$114.86 / $115.13
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: ACLX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When ACLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: ACLX is currently trading at $115.07, which is considered fair based on recent price action.
Technical Outlook: Technically, ACLX is in a strong uptrend. The price is currently testing key support at $114.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACLX is in a strong uptrend. The price is currently testing key support at $114.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
50/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
Trading Range & Key Levels
Support Level
$114.86
Resistance Level
$115.13
Current Trend
Strong Uptrend
Technical data as of
Apr 27, 2026
Protect Your Profits
ACLX is technically overbought (RSI 79). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($112.85)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-66.43
Wall Street Target
$112.85
(-1.9%)
Revenue Growth (YoY)
-89.2%
Share ACLX Analysis
Share this live ACLX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ACLX)
Bullish
2 Retail Mentions
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Feb 23, 2026
Daily AI digest
AI Retail Discussion Summary:
Gilead Sciences is acquiring CAR-T specialist Arcellx for $7.8bn, with an anticipated closure in Q2 2026. The deal comes as Gilead awaits FDA approval of Arcellx's lead candidate, anito-cel, for multiple myeloma treatment.
Key Retail Themes:
Acquisition of Arcellx by Gilead
FDA approval of anito-cel
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 3:17 PM ET
Data refreshes hourly during market hours. Next update: 4:17 PM
Data refreshes hourly during market hours. Next update: 4:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 61 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$689 | 56 HOLD |
|
RZLT
Rezolute Inc |
STRONG BUY
11 analysts |
$10 | 72 BUY |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
Advanced ACLX Option Strategies
Professional options setups generated by AI based on today's ACLX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ACLX Research Pages
